US Pre-Market Movers: BMY/AZN, GME, LNTH, BABA, SPCX, MT, FERG, EBAY, CRCL, BA, SBUX

The marquee item is the reported AstraZeneca/Bristol-Myers combination talks, and the price action fits the established template for large-cap pharma consolidation chatter: the presumed target or synergies beneficiary trades up, the presumed acquirer trades down on dilution and premium risk, with the spread between the two functioning as a crude read on how seriously the market prices completion. Pharma megamergers of this size have historically faced long regulatory and integration timelines, and early single-source reports of this kind frequently fail to progress, so the usual sequence is an initial gap followed by drift as confirmatory reporting does or does not arrive. Lantheus/Curium, by contrast, is a confirmed deal with a stated per-share price, which puts it in the arb bucket rather than the rumour bucket, and the stock should trade as a function of spread to the offer rather than on fundamentals. The GameStop convert-for-equity exchange is a familiar dilution mechanic for that name and the down move reflects the supply overhang; the SpaceX item pairs earnings with a lock-up expiry and elevated reported short interest, a combination that in past episodes has produced elevated volatility in both directions. The remaining items follow standard patterns: index inclusion buying ahead of the effective date tends to fade after the event, and the broker downgrades with large price-target cuts carry more weight than single-notch upgrades. The next tells are any confirmation or denial on the pharma talks and the flow around the SpaceX lock-up date.